Biocartis Group NV (FRA:8XB) Net Margin %: -105.98% (As of Jun. 2023)


FRA:8XB Biocartis Group NV FRA:8XB
14 GF Score
Price €0.26
View Full Analysis

What is Biocartis Group NV Net Margin %?

Biocartis Group NV FRA:8XB 14 Net Margin % is -105.98% as of Jun. 2023. GuruFocus rates FRA:8XB with a GF Score™ of 14/100.

Net margin is calculated as Net Income divided by its Revenue. Biocartis Group NV's Net Income for the six months ended in Jun. 2023 was €-31.25 Mil. Biocartis Group NV's Revenue for the six months ended in Jun. 2023 was €29.49 Mil. Therefore, Biocartis Group NV's net margin for the quarter that ended in Jun. 2023 was -105.98%.

The historical rank and industry rank for Biocartis Group NV's Net Margin % or its related term are showing as below:


FRA:8XB's Net Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -2.405
* Ranked among companies with meaningful Net Margin % only.

Biocartis Group NV  (FRA:8XB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Biocartis Group NV Net Margin % Related Terms

Biocartis Group NV Net Margin % Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV Net Margin % Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -173.14 -171.10 -145.92 -148.07 -113.74

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -170.59 -129.44 -109.13 -117.65 -105.98

FRA:8XB vs TMO, DHR, IDXX: Net Margin % Comparison

For the Diagnostics & Research subindustry, Biocartis Group NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocartis Group NV Net Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's Net Margin % distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's Net Margin % falls into.


FRA:8XB
14GF Score
Biocartis Group NV FRA:8XB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Biocartis Group NV's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-65.381/57.481
=-113.74 %

Biocartis Group NV's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin=Net Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-31.254/29.491
=-105.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -105.98% mean?
Biocartis Group NV (FRA:8XB) has a Net Margin % of -105.98% as of Jun. 2023. Net margin is the ratio of total net income to net sales. View historical data on Biocartis Group NV and its competitors.
Is Biocartis Group NV's Net Margin % too high?
Biocartis Group NV's current Net Margin % is -105.98%. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's Net Margin % compare to TMO and DHR?
Biocartis Group NV's Net Margin % of -105.98% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biocartis Group NV and its competitors. Biocartis Group NV's current Net Margin % is -105.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (FRA:8XB) has a current Net Margin % of -105.98%. The current Net Margin % is -105.98%. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biocartis Group NV (FRA:8XB), the current Net Margin % is -105.98% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for FRA:8XB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price